SciFluor Life Sciences Presents New Preclinical Data Highlighting Lead Program as a More Potent and Selective Treatment for Partial-Onset Seizure
Data for SF0034 Presented at 30th International Epilepsy Congress
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--SciFluor Life Sciences, a drug discovery and development company leveraging the transformational power of fluorine to enrich pipelines with innovative new therapeutics, today presented new preclinical data for SF0034, a novel potassium channel opener for the treatment of partial-onset seizure. Results show that SF0034 demonstrated a five-fold increase in potency, improved selectivity and a favorable pharmacological profile in a series of in vitro and in vivo preclinical models compared to ezogabine, a therapy currently approved in the U.S. and other global markets for the treatment of partial-onset seizure. These findings were presented by Scott Edwards, Ph.D., vice president, SciFluor, during a poster session held today at the 30th International Epilepsy Congress.
“As we continue to make advances with our Fluoropeutics portfolio, we are excited to share these new data on our lead compound in this series. The data demonstrate SF0034’s superior selectivity, potency and side effect profile in preclinical models compared to the currently marketed treatment for partial-onset seizure”
SF0034 is one of the lead compounds in the expanding SciFluor portfolio of FluoropeuticsTM. SciFluor scientists have discovered small-molecule new chemical entities (NCEs) by strategically introducing fluorine or fluorine groups into the molecular structure of known compounds directed toward precedented biological targets. SciFluor utilizes the incorporation of fluorine to create drugs with improved pharmacological profiles that provide important benefits over existing therapies. SF0034 was discovered by incorporating fluorine into ezogabine, an approved treatment for partial-onset seizure that must be administered three times a day. Data show that SF0034 is five times more potent with decreased QTc liabilities and a more balanced excretion proﬁle. In addition, SF0034 is less active at the potassium channel that causes urinary retention, potentially alleviating a key side effect of ezogabine.
“As we continue to make advances with our Fluoropeutics portfolio, we are excited to share these new data on our lead compound in this series. The data demonstrate SF0034’s superior selectivity, potency and side effect profile in preclinical models compared to the currently marketed treatment for partial-onset seizure,” said Arthur Hiller, chief executive officer of SciFluor. “These results provide early validation for our portfolio of fluorine-enhanced NCEs and illustrate the type of pipeline opportunities and preclinical data sets we expect to be presenting with other SciFluor drugs in the future. Fluoropeutics have the potential to greatly expand the number of innovative medicines across a wide range of therapeutic areas, including cardiovascular disease, infectious disease, CNS and oncology, and we are actively engaged in partnering discussions to support the broad potential of our fluorine-focused approach.”
The data presented today also show that SF0034 has a significantly lower likelihood of causing hERG-inhibition-related QT-prolongation, a common and potentially serious cardiovascular side effect of ezogabine. SF0034 also demonstrates higher human hepatocyte clearance than ezogabine, which may indicate that SF0034 would not require any dose adjustment in renally impaired patients.
To further build upon these findings, SciFluor has submitted SF0034 to the National Institute of Neurological Disorders and Stroke Anticonvulsant Screening Program to further characterize its pharmacological profile. The results of these studies will further define the potential of this compound as an improved potassium channel opener for use in the treatment of partial-onset seizures. In addition, an F-18 radiolabeled analog of SF0034 is available to aid in the preclinical and potentially clinical development of SF0034 by non-invasive PET imaging.
About SciFluor Life Sciences, LLC
SciFluor Life Sciences is the emerging leader in innovative fluorine-enabled drug discovery and development. The company is applying its expertise in fluorine chemistry, including breakthrough technology developed at Harvard University, to create Fluoropeutics™ – a proprietary portfolio of novel and differentiated small molecule drugs with improved pharmacological profiles based on approved medicines or clinical stage compounds targeting a range of therapeutic indications. SciFluor is also applying its capabilities to the development of novel 18F radiotracers that serve as imaging biomarkers to better inform decision-making throughout the development of the Fluoropeutics pipeline. SciFluor is funded by Allied Minds, a U.S. investment firm that deploys private equity to form, fund, manage and build start-ups based on early-stage technologies developed at renowned U.S. universities and federal research institutions. The company was founded in 2011 and is based in Cambridge, Mass. For more information, please visit www.scifluor.com.